- Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer.
- Chen MK.
- FEBS J. 2021 Feb 11. doi: 10.1111/febs.15730. Epub ahead of print.
- PMID: 33570247
- PubMed abstract
- Source abstract
- Commentary